What is a deviation in GMP?

Short answer

A GMP deviation is a documented departure from an approved instruction, specification, expected result, validated state or other controlled requirement. It should be recorded promptly, assessed for product quality and patient risk, investigated proportionately and reviewed through the site's Pharmaceutical Quality System.

What this means in practice

A deviation record should describe what happened, when and where it happened, what was affected and what immediate action was taken. The investigation should preserve the available evidence, assess the wider impact and determine the most likely or confirmed root cause before appropriate corrective or preventive action is agreed.

Not every deviation has the same significance. The depth of investigation and level of Quality oversight should be proportionate to the potential effect on patients, product quality, contamination control, data integrity and the validated state.

Regulatory guidance and site procedure

EU GMP Chapter 1 is regulatory guidance. It expects significant deviations to be recorded and investigated, with root cause determined using appropriate quality risk management principles. It does not prescribe one universal investigation tool or a single closure timescale for every event. The site's approved procedure should define responsibilities, escalation routes, target dates and approval requirements.

Evidence a robust deviation record normally contains

A clear factual description of the event.

Immediate correction, containment or other risk-control measures.

An assessment of affected and potentially affected products, batches, processes, systems and data.

The evidence examined and the rationale for the investigation conclusion.

The most likely or confirmed root cause, or a justified explanation where a definitive cause cannot be established.

Corrective and preventive actions where they are warranted.

Quality review, approval, trending and effectiveness follow-up.

Common weaknesses

Restating the event and calling it the root cause.

Defaulting to human error without examining the system, procedure, workload, training or equipment.

Closing the deviation before the wider impact has been assessed.

Creating actions that do not address the identified cause.

Repeated deviations without effective trending, escalation or management review.

Questions to ask internally

Is the record factual, complete and supported by contemporaneous evidence?

Has the potential effect on patients, product, data and validated state been assessed?

Were related events, trends and previous CAPA considered?

Does the conclusion follow from the evidence?

Are actions owned, risk-based and subject to appropriate effectiveness checks?

How W2 can help

W2 Cleanroom Consulting can independently review deviation investigations, challenge unsupported conclusions, assess links to contamination control and validated state, and help strengthen investigation and CAPA governance. The client remains responsible for Quality decisions, licence obligations, regulatory correspondence and approval through its own Pharmaceutical Quality System.

Need support with a deviation or recurring GMP issue?

Contact W2 Cleanroom Consulting at info@w2cleanrooms.com to discuss independent investigation review, inspection readiness or remediation support.

Prepared and reviewed by: W2 Cleanroom Consulting GMP team. Last reviewed: 24 July 2026.